

Dr Bianca SossenUniversity College London

Thurs 21st November, 12.00-1.00pm CTID Boardroom, LSTM



Diagnostic accuracy of a new urine LAM test in hospitalised HIV patients: SILVAMP TB LAM ('FujiLAM')

Bianca is a medical officer from South Africa (SA) who, after a few years of clinical work in Soweto, Johannesburg and then Khayelitsha in Cape Town, went on to study clinical epidemiology with an MSc in the 'Control of Infectious Diseases' from the London School of Hygiene and Tropical Medicine. Since that time she has worked on various observational studies and clinical trials relating to Tuberculosis and HIV, both in Cape Town and London. Several of these have considered the utility and impact of urine LAM assays, including that of the commercially-available Alere Determine TB-LAM (AlereLAM) and the 'next-generation' FujiLAM.

While the AlereLAM has demonstrated an important survival benefit in HIV-infected patients with advanced illness, uptake and use of this affordable test has been limited – partially due to constrained sensitivity (~42%). FujiLAM was developed to try to improve on this sensitivity, while maintaining specificity and a point-of-care, rapid design. This talk will unpack the evidence known around FujiLAM, centring on a study of its diagnostic accuracy in bio-banked urine samples. The talk will consider the practicalities of conducting this test and also highlight an upcoming prospective accuracy study, for which Cape Town will be one of six sites.